Palisade Capital Management LLC NJ Has $651,000 Position in Aerie Pharmaceuticals (AERI)

Palisade Capital Management LLC NJ increased its position in Aerie Pharmaceuticals (NASDAQ:AERI) by 18.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,000 shares of the company’s stock after buying an additional 1,900 shares during the quarter. Palisade Capital Management LLC NJ’s holdings in Aerie Pharmaceuticals were worth $651,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. QS Investors LLC purchased a new position in shares of Aerie Pharmaceuticals in the fourth quarter worth $125,000. Public Employees Retirement Association of Colorado purchased a new position in shares of Aerie Pharmaceuticals in the fourth quarter worth $176,000. Bamco Inc. NY increased its stake in shares of Aerie Pharmaceuticals by 19.4% in the fourth quarter. Bamco Inc. NY now owns 7,351 shares of the company’s stock worth $439,000 after buying an additional 1,195 shares during the period. California Public Employees Retirement System increased its stake in shares of Aerie Pharmaceuticals by 47.5% in the third quarter. California Public Employees Retirement System now owns 7,525 shares of the company’s stock worth $366,000 after buying an additional 2,425 shares during the period. Finally, Teacher Retirement System of Texas purchased a new position in shares of Aerie Pharmaceuticals in the fourth quarter worth $617,000.

In other Aerie Pharmaceuticals news, Director Gerald D. Cagle bought 1,000 shares of the company’s stock in a transaction dated Monday, May 21st. The shares were purchased at an average price of $50.25 per share, for a total transaction of $50,250.00. Following the acquisition, the director now owns 15,050 shares in the company, valued at approximately $756,262.50. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 10.53% of the company’s stock.

A number of research analysts have issued reports on AERI shares. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. HC Wainwright started coverage on shares of Aerie Pharmaceuticals in a research report on Friday, February 16th. They set a “buy” rating and a $78.00 price objective on the stock. Mizuho reissued a “buy” rating and set a $87.00 price objective on shares of Aerie Pharmaceuticals in a research report on Monday, January 29th. Canaccord Genuity boosted their price objective on shares of Aerie Pharmaceuticals from $73.00 to $86.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Finally, BidaskClub raised shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $77.92.

Shares of Aerie Pharmaceuticals stock opened at $49.85 on Wednesday. The company has a current ratio of 13.57, a quick ratio of 13.53 and a debt-to-equity ratio of 0.52. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -14.79 and a beta of 0.96. Aerie Pharmaceuticals has a 12-month low of $39.55 and a 12-month high of $66.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, May 8th. The company reported ($0.83) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.04. analysts forecast that Aerie Pharmaceuticals will post -3.75 earnings per share for the current year.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply